FDA Grants Zanubrutinib an Accelerated Approval in MZL FDA Grants Zanubrutinib an Accelerated Approval in MZL

The US Food and Drug Administration has granted an accelerated approval to zanubrutinib for the treatment of adult patients with relapsed or refractory marginal zone lymphoma.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news